Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer

Table 3

Efficacy evaluation after the treatment of MBC patients with MCT combined with 1E10 Aluminum/hydroxide vaccine.

Clinical response evaluation	MCT + 1E10 vaccine
	𝑛=21	%
CR	2	9,5
PR	3	14,3
SD	8	38,1
PD	8	38,1
TTP (95% CI, months)	9,82 (3,8–15,9)
OS (95% CI, months)	12,93 (7,8–19,9)
Response duration >12 months	10	76,9%